1. A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma. Issue 4 (21st March 2022) Authors: Yashar, David; Spektor, Tanya M.; Martinez, Daisy; Ghermezi, Matthew; Swift, Regina A.; Eades, Benjamin; Schwartz, Gary; Eshaghian, Shahrooz; Lim, Stephen; Vescio, Robert; Berenson, James R. Journal: Leukemia & lymphoma Issue: Volume 63:Issue 4(2022) Page Start: 975 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study. (25th April 2018) Authors: Gross, Zachary; Rahbari, Ashkon; Wirtschafter, Eric; Spektor, Tanya M.; Udd, Kyle A.; Bujarski, Sean; Ghermezi, Michael; Nosrati, Jason D.; Vidisheva, Aleksandra; Eades, Benjamin; Cecchi, Gary; Maluso, Tina; Swift, Regina; Berenson, James R. Journal: European journal of haematology Issue: Volume 100:Number 6(2018) Page Start: 621 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗